A Meta-Analysis of the Prognostic Value of Abnormally Expressed lncRNAs and Correlation with Clinicopathological Characteristics in Glioma
Objectives: Abnormal expression of lncRNAs are involved in the occurrence and development of glioma. Thus, we conducted a meta-analysis to clarify the prognostic value of lncRNAs in glioma integrally.
Methods: Pubmed, Web of Science, Embase, Cochrane Library, Clinical Trial.gov and Trip database were searched. Hazard ratio (HR) and 95% confidence intervals (CI) were calculated in the analysis of prognostic indicators. Odds ratio (OR) and 95%CI were applied to estimate the association between lncRNAs and clinicopathological features.
Results: The expression level of lncRNA was significantly correlated with the OS rate of glioma patients (HR=1.29, 95%CI: 1.03-1.61, p=0.03). The low expression of CASC2 (HR=0.42, 95%CI: 0.27-0.66, p=0.0001) showed a poor prognosis of glioma patients. MALAT1 (HR=1.42, 95%CI: 0.38-5.29, p=0.60), HOTAIR (HR=1.70, 95%CI: 0.69-4.21, p=0.25) and TUSC7 (HR=1.81, 95%CI: 0.87-3.75, p=0.11) have no statistical significance for the prognosis of glioma patients. The high expression of lncRNA was related to WHO staging (OR=0.31, 95%CI: 0.19-0.50, p<0.00001), EGFR expression (OR=3.14, 95%CI: 1.70-5.77, p=0.0002) and IDH1 status (OR=0.33, 95% CI: 0.12-0.93, p=0.04), while unrelated to age (OR=1.05, 95%CI: 0.78-1.42, p=0.75), gender (OR=1.01, 95%CI: 0.85-1.20, p=0.92), tumor size (OR=0.67, 95%CI: 0.35-1.27, p=0.22), PTEN (OR=0.26, 95%CI: 0.06-1.10, p=0.07), KPS score (OR=1.06, 95%CI: 0.44-2.59, p=0.90), MGMT promoter methylation (OR=2.05, 95%CI: 0.94-4.50, p=0.07) and the recurrence (OR=0.87, 95%CI: 0.42-1.82, p=0.72).
Conclusion: Abnormal expression of lncRNAs were related to survival of glioma patients and may serve as potential prognostic indicators in glioma. The higher expression level of lncRNAs, the worse prognosis of glioma. The expression of lncRNA CASC2 is correlated with the prognosis of glioma patients. The higher the expression level of CASC2, the better prognosis. LncRNAs are related to WHO staging, EGFR expression and IDH1 mutation, while unrelated to age, gender, tumor size, PTEN, KPS score, MGMT gene promoter methylation or tumor recurrence.
1.Morlando M, Ballarino M, Fatica A, Bozzoni I. The role of long noncoding RNAs in the epigenetic control of gene expression. Chemmedchem 2014;9:505–10.
2. Peng Q, Du X. The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol 2013;26:155– 65.
3. Fan F, Zhu Z, Gao C, Liu Y, Wang B, Wang Z, et al. Prognostic value of LncRNAs in lung carcinoma: A meta-analysis. Oncotarget 2017;8:83292–305.
4. Chen J, Chen Y, Gu L, Li X, Gao Y, Lyu X, et al. LncRNAs act as prognostic and diagnostic biomarkers in renal cell carcinoma: A systematic review and meta-analysis. Oncotarget 2016;7:74325–36.
5. Lei L, Wang J, Zhang L, Chen Y, Yuan P, Liu D. Meta-analysis of the clinical value of abnormally expressed long non-coding RNAs for pancreatic cancer. Oncotarget 2017;8:89149–59.
6. Cui X, Xuan J, Wu X. The prognostic value of long non coding RNAs in cervical cancer: A meta-analysis. Oncotarget 2017;8:62470–7.
7. Wang J, Du S, Wang J, Fan W, Wang P, Zhang Z, et al. The prognostic value of abnormally expressed LncRNAs in colorectal cancer: A meta-analysis. Plos One 2017;12:e0179670.
8. Cao S, Wang Y, Li J, Lv M, Niu H, Tian Y. Tumor-suppressive function of long noncoding RNA malat1 in glioma cells by suppressing mir-155 expression and activating fbxw7 function. Am J Cancer Res 2016;6:2561–74.
9. Chen W, Xu XK, Li JL, Kong KK, Li H, Chen C, et al. Malat1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing mir203 and promoting thymidylate synthase expression. Oncotarget 2017;8:22783–99.
10. Ma KX, Wang HJ, Li XR, Li T, Su G, Yang P, et al. Long noncoding RNA malat1 associates with the malignant status and poor prognosis in glioma. Tumour Biol 2015;36:3355–9.
11. Wang R, Li Y, Zhu G, Tian B, Zeng W, Yang Y, et al. Long noncoding RNA CASC2 predicts the prognosis of glioma patients and functions as a suppressor for gliomas by suppressing Wnt/β-catenin signaling pathway. Neuropsychiatr Dis Treat 2017;13:1805–13.
12. Liao Y, Shen L, Zhao H, Liu Q, Fu J, Guo Y, et al. LncRNA CASC2 interacts with miR-181a to modulate glioma growth and resistance to TMZ through PTEN pathway. J Cell Biochem 2017;118:1889–99.
13. Serghiou S, Kyriakopoulou A, Ioannidis JP. Long noncoding RNAs as novel predictors of survival in human cancer: a systematic review and meta-analysis. Mol Cancer 2016;15:50.
14. Reon BJ, Anaya J, Zhang Y, Mandell J, Purow B, Abounader R, et al. Expression of lncRNAs in low-grade gliomas and glioblastoma multiforme: an in silico analysis. PLoS Med 2016;13:e1002192.
15. Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815–34.
16. Hong Y, Rui T, Min Z, Jing W, Min D, Jie H. High expression of long noncoding RNA HULC is a poor predictor of prognosis and regulates cell proliferation in glioma. Onco Targets Ther 2017;10:113–20.
17. Zhuang JJ, Yue M, Zheng YH, Li JP, Dong XY. Long non-coding RNA MVIH acts as a prognostic marker in glioma and its role in cell migration and invasion. Eur Rev Med Pharmacol Sci 2016;20:4898–904.
18. Ma XL, Zhu WD, Tian LX, Sun WD, Shang F, Lin QT, et al. Long non-coding RNA tusc7 expression is independently predictive of outcome in glioma. Eur Rev Med Pharmacol Sci 2017:3605– 10.
19. Chen ZH, Hu HK, Zhang CR, Lu CY, Bao Y, Cai Z, et al. Downregulation of long non-coding RNA foxd3 antisense RNA 1 (foxd3-as1) inhibits cell proliferation, migration, and invasion in malignant glioma cells. Am J Transl Res 2016;8:4106–19.
20. Zhou X, Ren Y, Zhang J, Zhang C, Zhang K, Han L, et al. HO-TAIR is a therapeutic target in glioblastoma. Oncotarget 2015;6:8353–65.
21. Du P, Zhao H, Peng R, Liu Q, Yuan J, Peng G, et al. LncRNAXIST interacts with mir-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway. Biosci Rep 2017;37:BSR20170696.
22. Brodie S, Lee HK, Jiang W, Cazacu S, Xiang C, Poisson LM, et al. The novel long non-coding RNA TALNEC2, regulates tumor cell growth and the stemness and radiation response of glioma stem cells. Oncotarget 2017;8:31785–801.
23. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97–109.
24. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492–507.
25. Fan W, Zhang C, Cai J, Fan Y, Liang T, Yan X, et al. Upregulation of long noncoding RNA hoxa-as3 promotes tumor progression and predicts poor prognosis in glioma. Oncotarget 2017;8:53110–23.
26. Zhang JX, Han L, Bao ZS, Wang YY, Chen LY, Yan W, et al. HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma. Neuro Oncol 2013;15:1595–603.
27. Zuo J, Zhu K, Wang Y, Yu Z. MicroRNA-34a suppresses invasion and metastatic in esophageal squamous cell carcinoma by regulating CD44. Mol Cell Biochem 2018;443:139–49.
28. Ma CC, Xiong Z, Zhu GN, Wang C, Zong G, Wang HL, et al. Long non-coding RNA ATB promotes glioma malignancy by negatively regulating miR-200a. J Exp Clin Cancer Res 2016;35:90.
29. Zhao W, Sun C, Cui Z. A long noncoding RNA UCA1 promotes proliferation and predicts poor prognosis in glioma. Clin Transl Oncol 2017;19:735–41.
30. Wang Q, Zhang J, Liu Y, Wei Z, Zhou J, Ran D, et al. A novel cell cycle-associated LncRNA, hoxa11-as, is transcribed from the 5-prime end of the HOXA transcript and is a biomarker of progression in glioma. Cancer Letters 2016;373:251–9.
31. Lv QL, Chen SH, Zhang X, Sun B, Hu L, Qu Q, et al. Upregulation of long noncoding RNA zinc finger antisense 1 enhances epithelial-mesenchymal transition in vitro and predicts poor prognosis in glioma. Tumour Biol 2017;39:1010428317695022.
32. Gao K, Ji Z, She K, Yang Q, Shao L. Long non-coding RNA ZFAS1 is an unfavourable prognostic factor and promotes glioma cell progression by activation of the Notch signaling pathway. Biomed Pharmacother 2017;87:555–60.
33. Li Y, Gang Z, Wen Z, Wang J, Li Z, Bao W, et al. Long noncoding RNA AB073614 promotes the malignance of glioma by activating Wnt/β-catenin signaling through downregulating SOX7. Oncotarget 2017;8:65577–87.
34. Qureshi IA, Mattick JS, Mehler MF: Long non-coding RNAs in nervous system function and disease. Brain Res 2010;1338:20– 35.
35. Qureshi IA, Mehler MF: Long non-coding RNAs: Novel targets for nervous system disease diagnosis and therapy. Neurotherapeutics 2013;10:632–46.
36. Ping W, Xialin Z, Houliang D, Xiaoxia L, Li L, Aimin J. Roles of long noncoding RNAs in brain development, functional diversification and neurodegenerative diseases. Brain Res Bull 2013;97:69–80.